How AOD-9604 Works: Lipolysis Explained (2026)

AOD-9604 is a synthetic peptide that mimics the C-terminal fragment of human growth hormone. It specifically targets adipose tissue to stimulate lipolysis and inhibit lipogenesis, effectively reducing body fat without impacting blood sugar or IGF-1 levels. By enhancing metabolic signaling and fat oxidation, it promotes significant weight loss while maintaining an excellent safety profile for users.

For high-purity research peptides, Prime Lab Peptides offers premium-grade compounds specifically synthesized for scientific and metabolic research. Our commitment to rigorous testing and consistent quality ensures reliable data for every laboratory application. Explore our catalog today to find the precise tools needed for your next breakthrough.

How Does AOD-9604 Stimulate Lipolysis in Adipose Tissue?

AOD-9604 effectively stimulates lipolysis by activating specific metabolic pathways[1] within fat cells, primarily through the increased expression of beta-3 adrenergic receptors. This targeted activation triggers hormone-sensitive lipase, which efficiently breaks down stored triglycerides into free fatty acids. Consequently, the peptide accelerates fat oxidation and metabolic rate without negatively impacting insulin sensitivity or blood glucose levels.

cAMP Activation:

AOD-9604 increases intracellular cyclic AMP (cAMP) levels in adipocytes, which acts as a key signaling molecule in fat metabolism. This elevation activates protein kinase A, a central regulator of lipolysis. As a result, enzymatic processes that break down stored fat are accelerated, enhancing overall lipolytic efficiency.

Lipase Activation:

The peptide stimulates hormone-sensitive lipase within fat cells, which plays a direct role in fat breakdown. This enzyme targets stored triglycerides and converts them into free fatty acids and glycerol. Consequently, it enables efficient mobilization of stored fat, making it readily available for metabolic use.

Energy Utilization:

AOD-9604 promotes the release of fatty acids into circulation, allowing them to be transported to energy-demanding tissues. These fatty acids undergo oxidation in cellular mitochondria to produce energy. This process supports a metabolic shift from fat storage toward increased energy expenditure and improved metabolic activity.

How Does AOD-9604 Influence Metabolic Pathways Without Affecting Growth Hormone Receptors?

AOD-9604 strategically influences metabolism by mimicking the specific lipolytic region of human growth hormone. By avoiding interaction with growth hormone receptors[2], it prevents unwanted systemic hormonal effects like IGF-1 elevation or insulin resistance. Instead, it targets adipose tissue directly to stimulate fat breakdown, providing a focused metabolic enhancement that safely promotes fat loss without growth-related risks.

Additionally, this selective mechanism allows targeted fat metabolism without altering glucose regulation. Studies indicate that AOD-9604 promotes fat oxidation and energy expenditure while maintaining insulin sensitivity, aligning with established research standards for safety and metabolic specificity, making it a unique compound for metabolic research focused on adipose-specific activity.

What Role Does AOD-9604 Play in Inhibiting Lipogenesis?

AOD-9604 effectively inhibits lipogenesis by downregulating the specific enzymes responsible for converting excess dietary nutrients into stored adipose tissue. By suppressing these lipogenic pathways, it significantly reduces new fat formation. Simultaneously, it promotes active fat breakdown through lipolysis, creating a dual-action metabolic environment that favors a leaner body composition without interfering with systemic growth hormone levels.
Key mechanisms involved include:

• Reduction in enzymes responsible for triglyceride synthesis
• Suppression of pathways that convert glucose into stored fat
• Enhanced signaling for fatty acid breakdown and mobilization
• Maintenance of metabolic balance without affecting GH receptors

This dual-action mechanism, derived from its origin as a growth hormone[3] fragment, creates a metabolic environment where fat accumulation is minimized. By limiting triglyceride synthesis and enhancing fatty acid release, AOD-9604 supports a shift toward energy utilization rather than fat storage in metabolic study models. This improves metabolic efficiency and allows researchers to better analyze fat metabolism pathways and energy balance dynamics.

How Is AOD-9604 Used in Scientific Metabolic Research Models?

AOD-9604 is extensively used in metabolic research to study fat reduction [4], energy expenditure, and complex adipose tissue signaling. Its unique ability to enhance lipolysis and fat oxidation in experimental models makes it a vital tool for understanding obesity. By isolating these specific metabolic pathways, researchers can investigate targeted fat loss without the systemic hormonal risks.

Animal studies have demonstrated reduced body weight gain and increased fat metabolism without adverse effects on insulin sensitivity. Researchers use it to investigate obesity-related pathways, adipocyte function, and potential therapeutic targets for metabolic disorders. This makes AOD-9604 a valuable tool for studying safe fat reduction mechanisms and long-term metabolic regulation.

Choose Prime Lab Peptides for Reliable Metabolic Compounds

Researchers struggle with reliable metabolic compounds due to inconsistent peptide purity, poor manufacturing standards, and a lack of transparent testing data. These issues directly impact experimental accuracy, reproducibility, and overall research outcomes, especially in sensitive areas like lipolysis and metabolic pathway analysis.

The solution is choosing a trusted provider like Prime Lab Peptides. Their rigorously tested compounds ensure high purity, batch-to-batch consistency, and reliable performance in every experiment. With strict quality control and verified standards, you can conduct precise metabolic research confidently while achieving reproducible, accurate, and scientifically valid outcomes across all studies.

What the β3-Adrenergic Knockout Studies Show About the Mechanism

They show that the lipolytic action is not delivered directly through the β3-adrenergic receptor, even though the peptide raises that receptor's expression. The distinction comes from a single study design, and it is the strongest mechanistic evidence in the AOD-9604 literature.

Heffernan and colleagues treated obese mice for 14 days and observed reduced body weight and body fat alongside increased β3-AR messenger RNA in fat tissue. In obese animals, β3-AR expression is normally repressed; both intact human growth hormone and AOD-9604 raised it back to levels comparable with lean mice. That part matches what the hub describes above.

The knockout arm is what the assertion alone cannot deliver. In mice lacking the β3-adrenergic receptor entirely, chronic treatment failed to reproduce the body weight change and the increase in lipolysis seen in wild-type controls. Yet in an acute experiment in those same knockout animals, AOD-9604 still increased energy expenditure and fat oxidation.

Two readings follow, and they are not the same claim. Long-term remodelling of fat mass appears to need an intact β3-adrenergic pathway. The immediate rise in energy expenditure and fat oxidation does not — something else carries it, and that something has not been identified. The authors' own conclusion was that the lipolytic actions are not mediated directly through β3-AR, while the increase in β3-AR expression may subsequently contribute to enhanced lipolytic sensitivity.

This is mouse data. No equivalent receptor-expression work in human adipose tissue has been published for this peptide. Heffernan et al., Endocrinology, 2001.

How Growth Hormone Receptor Independence Was Actually Tested

By two in vitro assays run alongside the animal work: a competitive radioligand binding assay and a cell proliferation assay, both in BaF-B03 cells transfected with the human growth hormone receptor. AOD-9604 did not compete with labelled human growth hormone for the receptor, and it did not induce cell proliferation — where intact growth hormone did both.

The distinction matters more than it looks. An unchanged circulating IGF-1 level is a downstream marker: it can stay flat because of dose, timing, or sampling window. A receptor-level negative is a different order of evidence — no displacement of the labelled hormone, and no proliferative response in a cell line engineered so that the transfected growth hormone receptor is the relevant target. That is what turns the hub's statement into a demonstration.

The same study reported the metabolic contrast in vivo. In obese mice, both growth hormone and AOD-9604 reduced body weight gain, increased fat oxidation and raised plasma glycerol as an index of lipolysis. But unlike growth hormone, AOD-9604 did not induce hyperglycaemia and did not reduce insulin secretion. The authors framed this as evidence that growth hormone behaves as a pro-hormone whose fragments act through pathways distinct from the intact molecule.

What remains open is the positive half of the question. No binding partner, receptor or transporter has been identified for AOD-9604 in the published literature. "Growth hormone receptor independent" describes what has been excluded, not what has been found. Heffernan et al., International Journal of Obesity, 2001.

Antilipogenic vs Lipolytic: What the Early Fragment Studies Separated

The parent sequence's best-documented effect is on fat synthesis, not fat breakdown — and one of the founding studies found no lipolytic effect at all. That is a real tension in the record, and it shapes how the lipogenesis question above should be read.

Working on the synthetic C-terminal sequence hGH 177-191, Wu and Ng reported antilipogenic activity identical to that of intact growth hormone, while detecting no significant lipolytic effect by glycerol release from epididymal fat pads of treated rats. Their conclusion was that growth hormone's main physiological effect on lipid metabolism sits at the level of lipogenesis (Wu & Ng, 1993).

A companion study proposed a mechanism for that suppression. In adipocytes isolated from obese Zucker rats, the same peptide reduced both basal and insulin-stimulated 2-deoxyglucose uptake, and at equimolar concentrations was more potent than intact growth hormone. Less glucose entering the adipocyte means less substrate available for triglyceride synthesis (Wijaya & Ng, 1993). Chronic treatment of ob/ob mice with the same fragment reduced cumulative body weight gain, decreased adipose tissue mass, and significantly inhibited lipogenesis in fat tissue (Natera et al., 1994).

AOD-9604 is that C-terminal region with an added N-terminal tyrosine, and it did raise plasma glycerol in vivo in later mouse work. So the two readings are not interchangeable — they come from different preparations, species, routes and readouts. One caution for anyone citing enzyme-level detail: no published AOD-9604 study reports measurements of acetyl-CoA carboxylase or fatty acid synthase.

Lipid Droplet Turnover: What the Data Show and Where They Stop

The published AOD-9604 record is whole-tissue and whole-animal, not organelle-level. That boundary is worth stating plainly, because triglyceride turnover is often discussed at a resolution the data do not reach.

What has actually been measured across the AOD-9604 studies:

• Body weight gain and adipose tissue mass
• Lipolytic activity of adipose tissue
• Plasma glycerol, used as an index of lipolysis
• Plasma glucose and insulin
• Resting energy expenditure, fat oxidation and glucose oxidation by indirect calorimetry
• β3-adrenergic receptor messenger RNA in fat tissue

What has not been measured in any AOD-9604 publication indexed on PubMed: perilipin phosphorylation, sequential ATGL, HSL and MGL activity at the droplet surface, carnitine-shuttle or acyl-CoA dehydrogenase transcription, respiratory exchange ratio shifts, adipocyte droplet-size histology, or transcriptional profiling of adipocyte gene clusters.

The enzymes themselves are well characterised in general adipocyte biology — adipose triglyceride lipase initiates triglyceride cleavage, hormone-sensitive lipase processes the diacylglycerol intermediate, monoacylglycerol lipase releases the glycerol backbone, and perilipin coating governs lipase access to the stored core. Attributing specific movements in that cascade to AOD-9604, however, goes past what has been published. Anything asserted at droplet scale for this peptide is inference from downstream flux measurements, not direct observation.

For a research audience, that gap is the useful information: droplet-resolution work on AOD-9604 is an open experiment, not a settled result.

Which Research Models the AOD-9604 Results Come From

Two rodent obesity models, one receptor knockout line, and one transfected cell line. That is the whole peer-reviewed base, and knowing its size is the first step in reading any claim about this peptide.

• Obese Zucker rats. Daily oral administration over 19 days reduced cumulative body weight gain by more than half compared with controls (15.8 ± 0.6 g versus 35.6 ± 0.8 g), with increased lipolytic activity in adipose tissue. Crucially, euglycemic clamp testing found no adverse effect on insulin sensitivity, in contrast with chronic treatment using intact growth hormone. That clamp is the strongest published glucose measurement behind the adipose-specific framing — a direct sensitivity measure rather than a fasting value (Ng et al., Hormone Research, 2000).
• ob/ob and lean C57BL/6J mice. Fourteen days by mini-osmotic pump, with indirect calorimetry for substrate oxidation and energy expenditure.
• β3-adrenergic receptor knockout mice, used to test whether the receptor is required.
• BaF-B03 cells transfected with the human growth hormone receptor, for binding and proliferation assays.

On the human side, development reached phase IIa by early 2002 (Wilding, 2004), and a 2006 review of obesity compounds in clinical development still listed AOD-9604 among candidates that had not completed phase III (Halford, 2006). No randomized efficacy trial of AOD-9604 in obesity is indexed on PubMed. The human-subject literature that is indexed concerns analytical detection, not metabolic outcomes.

How Long AOD-9604 Persists, and What It Breaks Down Into

The parent peptide is short-lived relative to at least one of its own fragments — which is the single most practical stability finding in the literature, and it comes from anti-doping analytical work rather than metabolic research.

Cox and colleagues incubated AOD-9604 in serum and urine and identified six potential metabolites. Quantification in serum singled out one of them, the nonapeptide CRSVEGSCG, as significantly more stable than the other metabolites and than the parent compound itself. The consequence they draw is methodological: screening for that metabolite alongside the parent widens the detection window. Their validated urine extraction method reached a limit of detection of 50 pg/mL (Cox et al., Drug Testing and Analysis, 2014).

The same paper gives the precise structural definition: the growth hormone C-terminal fragment spanning residues 177-191, carrying an additional tyrosine at the N-terminus. Sixteen residues in total, which is why the human safety literature refers to it as a hexadecapeptide.

Two further points matter for laboratory planning. AOD-9604 is on the World Anti-Doping Agency prohibited list. And it does not influence the WADA growth hormone isoform immunoassay — it is neither captured by nor confounding to standard growth hormone testing, so it requires its own targeted assay (Orlovius et al., 2013).

For anyone designing sampling schedules, instability of the parent compound is the constraint, and metabolite tracking is the published workaround.

What the Selectivity Data Do Not Cover

Adipose selectivity is an observation made in specific models, not a structural guarantee — and the same C-terminal region has documented activity outside fat tissue. Anyone treating metabolic compartmentalisation as settled should know where the counter-evidence sits.

Wade and colleagues assayed a series of C-terminal shortened fragments and found that the reduced, S-carbamidomethylated form of hGH 177-191 caused significant hyperglycaemia and insulin resistance in normal rats at nanomolar quantities, placing an insulin-antagonistic core within residues 178-190 (Wade et al., Acta Endocrinologica, 1982). Separately, injected hGH 177-191 shifted muscle glycogen synthase from its active to its inactive form in rat skeletal muscle by inactivating glycogen synthase phosphatase, with no change in muscle cyclic AMP (Macaulay et al., Archives of Biochemistry and Biophysics, 1983).

Neither result has been reproduced with AOD-9604, and the rodent work with AOD-9604 specifically found glucose handling and insulin sensitivity unchanged. But these findings rest on essentially the same amino acid sequence, in different chemical preparations and different tissues. That is a live methodological question rather than a closed one, and it argues for measuring non-adipose endpoints rather than assuming them flat.

One further limit: the AOD-9604 exposure periods in the published record run 14 to 19 days in rodents. Whether the selectivity observed over that window holds over longer exposure, or in human tissue, has not been established.

FAQs

What is AOD-9604 peptide used for in research?
AOD-9604 is used in research to study fat metabolism, lipolysis, and obesity-related biological pathways. It helps researchers analyze how adipose tissue responds to metabolic stimulation, enhances fat oxidation processes, and supports investigations into safe and targeted fat reduction mechanisms.

Does AOD-9604 affect insulin sensitivity?
AOD-9604 does not significantly affect insulin sensitivity in most research findings. Studies show it promotes fat metabolism and lipolysis without disrupting glucose regulation, making it suitable for metabolic research models that require stable insulin response and balanced energy metabolism.

Is AOD-9604 similar to human growth hormone?
AOD-9604 is a modified fragment of human growth hormone that mimics its fat-burning properties. However, it does not bind to growth hormone receptors or stimulate IGF-1 production, allowing targeted lipolytic effects without systemic hormonal changes in research settings.

How does AOD-9604 enhance fat oxidation?
 AOD-9604 enhances fat oxidation by stimulating lipolysis and increasing the release of free fatty acids into circulation. These fatty acids are then utilized as energy within cells, improving metabolic efficiency and supporting detailed studies of fat utilization and energy balance.

References:

1- Nelson, A. E., Meinhardt, U., Hansen, J. L., Birzniece, V., Clifford, D., & Ho, K. K. Y. (2014). Pharmacokinetics and metabolism of AOD9604 in human subjects. Clinical Endocrinology, 81(3), 324–330. https://pubmed.ncbi.nlm.nih.gov/25208511/

2- Ng, F. M., & colleagues. (2022). Human growth hormone fragment (176–191) and its metabolic effects. International Journal of Molecular Sciences, 23(13), 1–15. https://pmc.ncbi.nlm.nih.gov/articles/PMC9249349/

3- Brooks, A. J., & Waters, M. J. (2018). The growth hormone receptor: Mechanism of activation and signal transduction. International Journal of Molecular Sciences, 19(5), 1–20. https://pmc.ncbi.nlm.nih.gov/articles/PMC5816795/

4- Heffernan, M. A., Thorburn, A. W., Fam, B., Summers, R. J., & Ng, F. M. (2001). Increase of fat oxidation and weight loss in obese mice treated with a growth hormone fragment. Endocrinology, 142(12), 5182–5189. https://pubmed.ncbi.nlm.nih.gov/11673763/